Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A phase 3 trial

Name: Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A phase 3 trial
Creator: Andrew Blauvelt
Published: 2024-04-18T12:22:33.339Z
Keywords: Medicine, Dermatology, Seborrheic Dermatitis

Blauvelt, Andrew; Alonso-Llamazares, Javier; Bhatia, Neal; Draelos, Zoe; DuBois, Janet; Forman, Seth; Gooderham, Melinda; Green, Lawrence; Guenthner, Scott; Hebert, Adelaide; Lain, Edward; Moore, Angela; Papp, Kim; Stein Gold, Linda; Zirwas, Matthew; Kato, Saori; Snyder, Scott; Krupa, David; Burnett, Patrick; Berk, David; Chu, David

doi:10.17632/szgrykznrm.2

Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A phase 3 trial

Published: 18 April 2024| Version 2 | DOI: 10.17632/szgrykznrm.2

Contributors:

Andrew Blauvelt, Javier Alonso-Llamazares, Neal Bhatia, Zoe Draelos, Janet DuBois, Seth Forman, Melinda Gooderham, Lawrence Green, Scott Guenthner, Adelaide Hebert, Edward Lain, Angela Moore, Kim Papp, Linda Stein Gold, Matthew Zirwas, Saori Kato, Scott Snyder, David Krupa, Patrick Burnett, David Berk, David Chu

Description

Supplementary data to support the primary manuscript “Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blind, vehicle-controlled, phase 3 trial”

Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A phase 3 trial

Description

Files

Categories

Licence